en
James Davies

Cracked: Why Psychiatry is Doing More Harm Than Good

Avisarme cuando se agregue el libro
Para leer este libro carga un archivo EPUB o FB2 en Bookmate. ¿Cómo puedo cargar un libro?
Why is psychiatry such big business? Why are so many psychiatric drugs prescribed — 47 million antidepressant prescriptions in the UK alone last year — and why, without solid scientific justification, has the number of mental disorders risen from 106 in 1952 to 374 today?
The everyday sufferings and setbacks of life are now 'medicalised' into illnesses that require treatment — usually with highly profitable drugs. Psychological therapist James Davies uses his insider knowledge to illustrate for a general readership how psychiatry has put riches and medical status above patients' well-being. The charge sheet is damning: negative drug trials routinely buried; antidepressants that work no better than placebos; research regularly manipulated to produce positive results; doctors, seduced by huge pharmaceutical rewards, creating more disorders and prescribing more pills; and ethical, scientific and treatment flaws unscrupulously concealed by mass-marketing.
Cracked reveals for the first time the true human cost of an industry that, in the name of helping others, has actually been helping itself.
Este libro no está disponible por el momento.
347 páginas impresas
Propietario de los derechos de autor
Bookwire
Publicación original
2013
Año de publicación
2013
Editorial
Icon Books
¿Ya lo leíste? ¿Qué te pareció?
👍👎

Citas

  • Aniecompartió una citael año pasado
    Was this just an isolated example, or is it quite representative?
  • Aniecompartió una citael año pasado
    In other words, despite the damning research about antidepressant efficacy, and despite the NICE recommendations that we pull back on antidepressant use, continued regulatory approval has allowed prescriptions to just keep going up and up. Of course, this raises uncomfortable questions regarding the precise relationship between the regulatory agencies and the pharmaceutical industry. Do the agencies have an incentive to set the bar so low?
  • Aniecompartió una citael año pasado
    Given the results of studies outlined above, why do the regulatory agencies that evaluate antidepressants continue to approve these drugs for public use? Well, the key to answering this question is to realise that the regulatory agencies do not take into account the results of negative trials when deciding whether to approve an antidepressant.

En las estanterías

fb2epub
Arrastra y suelta tus archivos (no más de 5 por vez)